Regeneron founder, chairman and CEO Dr. Leonard Schleifer joins 'Squawk Box' to discuss the company's bid for 23andMe, ...

Regeneron said on Monday its experimental drug helped patients preserve up to 51% of lean mass and lose more fat when used in ...

Market Domination Overtime hosts Julie Hyman and Josh Lipton preview the top market stories and headlines Wall Street will be paying attention to tomorrow, Friday, June 13, including June's ...

In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 13 Biotech Stocks with Huge Upside Potential. JPMorgan has ...

Regeneron Pharma stock has been in a persistent downtrend for over 280 days. Here's why you should avoid REGN.

Regeneron’s shares have declined nearly 17% following the failure of the company’s Dupixent follow-up itepekimab.

A key decision by the bankruptcy judge could help with protecting consumer data, write Diane Lourdes Dick and Anya Prince.

Regeneron Pharmaceuticals is to enter an in-licensing agreement with Hansoh Pharmaceuticals to secure exclusive rights for HS ...

Regeneron shares fell nearly 18% on Friday after its experimental drug for patients with a type of lung condition commonly ...

Regeneron isn’t the only Big Pharma to spot potential in Hansoh’s obesity pipeline. Merck & Co. ended last year paying $112 ...

Regeneron highlighted that about 35% of weight loss from semaglutide alone was due to lean mass loss, which combo therapies ...